Clinical Trials Directory

Trials / Completed

CompletedNCT00322231

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects With a History of Herpes Zoster

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
101 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.

Conditions

Interventions

TypeNameDescription
BIOLOGICALzoster vaccine live (ZOSTAVAX™)1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
BIOLOGICALComparator: Placebo1 dose 0.65 mL/dose subcutaneous injection of placebo.

Timeline

Start date
2006-05-01
Primary completion
2007-07-01
Completion
2007-07-01
First posted
2006-05-05
Last updated
2015-01-26
Results posted
2010-12-15

Source: ClinicalTrials.gov record NCT00322231. Inclusion in this directory is not an endorsement.